Drug Profile
Efletirizine
Alternative Names: UCB 28754Latest Information Update: 02 Jun 2010
Price :
$50
*
At a glance
- Originator UCB
- Class Acetates; Antiallergics; Antihistamines; Piperazines; Small molecules
- Mechanism of Action Histamine H1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic urticaria; Seasonal allergic rhinitis
Most Recent Events
- 07 Jun 2005 Discontinued - Phase-II for Seasonal allergic rhinitis in USA (Intranasal)
- 11 Feb 2005 UCB has completed a proof of concept trial of the once-daily formulation of efletirizine
- 06 Jan 2004 UCB has completed phase III trials of twice-daily efletirizine in seasonal allergic rhinitis and Chronic urticaria